glp 1 ncbi Glucagon-like peptide-1 receptor agonists and muscle mass effects GLP-1 actions and target organs.

It's designed to target dull, rough skin texture and loss of elasticity

Clinical trials demonstrate substantial reductions in waist circumference and visceral fat alongside total body weight loss

Twelve-week treatment with liraglutide as add-on to insulin in normal-weight patients with poorly controlled type 1 diabetes: A randomized, placebo-controlled, double-blind parallel study

One study has also found that the risk of heart disease, heart attack, and stroke increased after people stopped taking a GLP-1

Although the FDA has yet to approve a closed-loop artificial pancreas system, research is ongoing and these devices will likely become increasingly available in the coming years as technology improves (FDA 2016)